Gavi the Vaccine Alliance (GAVI)

Accelerating equitable uptake and coverage of vaccinescountries immunised 64 million unique children with Gavi support in 2020. Of this number, each child is protected against approximately seven infectious disease. Today, nearly four in five children in gavi-supported countries receive routine immunisation. Due to the impact of the covid-19 pandemic, coverage with a full course of pentavalent Vaccine and the first dose of measles-containing Vaccine both decreased to 78% in gavi-supported countries, from 82% and 81%, respectively a declines less severe than what was feared.gavi supported 21 Vaccine introductions and campaigns in 2020, a decrease from 60 in 2019 due to the impact of the covid-19 pandemic.in 2020, emergency stockpiles for cholera, meningococcal and yellow fever vaccines were accessed a total of 11 times by 9 countries.increasing the effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systemswhere available, monthly administration data suggests that despite a 40% reduction in immunisation activity during the first wave of the covid-19 pandemic in april and may 2020, routine immunisation bounced back: by december 2020, monthly immunisation rates were above those of the previous year.gavi disbursed a record of us$ 383 million in health system support in 2020. Annual health system strengthening (hss) disbursements nearly doubled over the course of Gavi 4.0, totalling us$ 1.42 billion for the 2016-2020 strategic period compared to the original board-approved envelope of us$ 1.3 billion.the time taken to disburse cash grants to countries improved significantly, from 18 months in 2018 to an average of slightly under 10 months in 2020, which is closer to the target of 9 months. When including grants that were delayed by audit and supply constraints, the average was 14 months.improving sustainability of national immunisation programmesa testament to increasing country ownership and the long-term financial sustainability of gavi-supported vaccines, 100% of countries paid their 2020 co-financing obligations on time (excluding the nine countries that received an exceptional waiver due to the covid-19 pandemic).by the end of 2020, 88% of countries in the accelerated transition phase were on track to transition successfully. This is an increase from 67% in 2019, exceeding the target of 75% by 2020. the only country that missed the criteria to be considered on track for successful transition did so because of its dtp3 coverage level. This highlights the importance of our programmatic sustainability work with countries, which will be further expanded in Gavi 5.0. Shaping markets for vaccines and other immunisation productsin 2020, the weighted average price to fully immunise a child with pentavalent, pneumococcal and rotavirus vaccines fell to us$ 15.20, a reduction of 24% since 2015 and a 2% drop from the previous year.by the end of 2020, 10 out of 11 Vaccine markets were assessed as having sufficient and uninterrupted supply up from 8 in 2019. While supply security for inactivated polio Vaccine and oral cholera Vaccine was re-established, global demand for human papillomavirus Vaccine continues to outpace available supply, despite the manufacturing capacity expansion efforts of a major supplier to gavi.further information on Gavi's progress towards achieving its strategic goals can be found in its 2020 annual progress report, online at: httpswwwgaviorgprogrammesimpactou...